



Michael Khodadoust

Assistant Professor of Medicine (Oncology) and of Dermatology
Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Medicine**

300 Pasteur Dr Rm JC007

Stanford, CA 94305

Tel (650) 725-5071 Fax (650) 725-8381

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Donna Galvez - Senior Administrator –Med/Onc

Email drgalvez@stanford.edu

Tel 650-721-1503

Bio

CLINICAL FOCUS

- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Medicine - Oncology
- Assistant Professor - University Medical Line, Dermatology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- Young Investigator Award, Journal of Clinical Oncology, Conquer Cancer Foundation (2015)
- Fellow Award, Leukemia and Lymphoma Society (2014-)
- Dean's Postdoctoral Fellowship, Stanford University (2014)
- Distinction in Academics and Research, University of Michigan, Ann Arbor (2010)
- William Dodd Robinson Award, University of Michigan, Ann Arbor (2010)
- Membership, Alpha Omega Alpha (2009)
- Predoctoral Fellowship Award, National Science Foundation (2002)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, Research Advisory Council, Cutaneous Lymphoma Foundation (2019 - present)
- Steering Committee, Chair, San Francisco Lymphoma Rounds, Lymphoma Research Foundation (2020 - present)
- Board Member, International Society of Cutaneous Lymphomas (2020 - present)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Hematology and Oncology Fellowship (2015) CA
- Residency: Stanford University Internal Medicine Residency (2012) CA
- Internship: Stanford University Internal Medicine Residency (2011) CA

- Board Certification: Medical Oncology, American Board of Internal Medicine (2017)
- Board Certification, Oncology , American Board of Internal Medicine (2017)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2013)
- PhD, University of Michigan , Immunology (2010)
- Medical Education: University of Michigan Health System (2010) MI

LINKS

- Khodadoust Lab website: <http://med.stanford.edu/khodadoustlab.html>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- Phase I ONO-4685 Given as Monotherapy in Relapsed or Refractory T Cell Lymphoma, Recruiting
- Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease , Recruiting
- Intratumoral Injection of SD-101 in Combo w/ Ibrutinib & Local Radiation in Follicular Lymphoma, Not Recruiting
- Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody, Not Recruiting
- Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL, Not Recruiting
- Phase 1/2A Cerdulatinib (PRT062070) in Relapsed/Refractory CLL or SLL B-Cell or T-Cell NHL , Not Recruiting
- Phase 2 MK-3475 in the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome, Not Recruiting
- Phase I Duvelisib in Combo w/ Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas, Not Recruiting
- Phase I IPH4102 (Humanized Anti-KIR3DL2 mAb) in Relapsed/Refractory Cutaneous T-Cell Lymphomas, Not Recruiting
- Phase I MRG-106 After Local Intratumoral+Subcutaneous+IV Administration in Lymphomas & Leukemias, Not Recruiting
- Phase I/II BTK Inhibitor Ibrutinib in Combo w/ MEDI4736 in Relapsed or Refractory Lymphomas, Not Recruiting
- Phase I/II Immunostimulatory CpG +Intratumoral Ipilimumab + in Combo w/ Radiation in B-cell Lymphoma, Not Recruiting
- Phase I/II Intratumoral Injections of SD-101 in Combo w/ Radiation in Low-grade B-cell Lymphoma, Not Recruiting
- Phase I/II KTE-C19 in Combo w/ Atezolizumab in Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Not Recruiting
- Phase I/II KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma, Not Recruiting
- Phase Ib/II Hu5F9-G4(Magrolimab) +/- Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma, Not Recruiting
- Phase II CD11301 0.03% & 0.06% Gel in Tx of Cutaneous T-Cell Lymphoma(CTCL) Stages IA, IB & IIA, Not Recruiting
- Phase II MK-3475 (Pembrolizumab) & Interferon Gamma 1-b +/- Immunotherapy in MF/SS/ASS, Not Recruiting
- Phase II NM-IL-12 (rHuIL-12) in Cutaneous T Cell Lymphoma +Low Dose Total Skin Electron Beam Therapy, Not Recruiting
- Phase III Axicabtagene Ciloleucef vs SoC Therapy in Relapsed/Refractory Diffuse Large BCell Lymphoma, Not Recruiting
- Phase III Topical Naloxone Hydrochloride Lotion 0.5% in MF or SS Forms of Cutaneous T-Cell Lymphoma, Not Recruiting
- SD-101 in Combo w/ BMS-986178 & Local Radiation in Low-Grade B-Cell Lymphomas, Not Recruiting

Teaching

STANFORD ADVISEES

Postdoctoral Faculty Sponsor

Armando Bastidas Torres

Doctoral Dissertation Reader (NonAC)

Aaron Trotman-Grant

Postdoctoral Research Mentor

Armando Bastidas Torres, Eric Mou

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Hematology (Fellowship Program)
- Immunology (Phd Program)
- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine.** *Blood*
Hosoya, H., Bastidas Torres, A. N., Fernandez-Pol, S., Gubatan, J. M., Najidh, S., Duran, G. E., Dong, F., Ehlinger, Z., Lohman, C., Wright, C., Sahaf, B., Mackall, C. L., Miklos, et al
2025
- **Genetic alteration of class I HLA in cutaneous T-cell lymphoma.** *Blood*
Kwang, A. C., Duran, G. E., Fernandez-Pol, S., Najidh, S., Li, S., Bastidas Torres, A. N., Wang, E. B., Herrera, M., Bandali, T. I., Kurtz, D. M., Kim, Y. H., Khodadoust, M. S.
2024
- **Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.** *American journal of hematology*
Mou, E., Fernandez-Pol, S., Li, S., Rieger, K. E., Novoa, R., Suarez, C. J., Wieland, R., Weng, W., Kim, Y. H., Khodadoust, M. S.
2024
- **Integrating Novel Agents into the Treatment of Advanced Mycosis Fungoides and Sézary Syndrome.** *Blood*
Khodadoust, M. S., Mou, E., Kim, Y. H.
2022
- **Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.** *Oncoimmunology*
Su, T., Duran, G. E., Kwang, A. C., Ramchurren, N., Fling, S. P., Kim, Y. H., Khodadoust, M. S.
2022; 11 (1): 2115197
- **Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma.** *Blood*
Beygi, S., Duran, G. E., Fernandez-Pol, S., Rook, A. H., Kim, Y. H., Khodadoust, M. S.
2022
- **Pembrolizumab in mycosis fungoides with PD-L1 structural variants.** *Blood advances*
Beygi, S. n., Fernandez-Pol, S. n., Duran, G. n., Wang, E. B., Stehr, H. n., Zehnder, J. L., Ramchurren, N. n., Fling, S. P., Cheever, M. A., Weng, W. K., Kim, Y. H., Khodadoust, M. S.
2021; 5 (3): 771–74
- **Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Khodadoust, M. S., Rook, A. H., Porcu, P. n., Foss, F. n., Moskowitz, A. J., Shustov, A. n., Shanbhag, S. n., Sokol, L. n., Fling, S. P., Ramchurren, N. n., Pierce, R. n., Davis, A. n., Shine, et al
2019: JCO1901056
- **B cell lymphomas present immunoglobulin neoantigens.** *Blood*
Khodadoust, M. S., Olsson, N. n., Chen, B. n., Sworder, B. n., Shree, T. n., Liu, C. L., Zhang, L. n., Czerwinski, D. K., Davis, M. M., Levy, R. n., Elias, J. E., Alizadeh, A. A.
2018
- **Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens** *NATURE*
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A., Chen, B., Swaminathan, K., Rawson, K., Liu, C. L., Steiner, D., Lund, P., Rao, S., Zhang, L., Marceau, et al

2017; 543 (7647): 723-?

- **Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-Cell Lymphoproliferative Disorders.** *The American journal of surgical pathology*
Bulterys, P., Zhou, C. W., Gong, S., Gars, E., Zhang, J., Younes, S., Stone, A., Hirt, C., Marks, L., Su, C., Stehr, H., Lawrence, L., Tan, et al
2026; 50 (5): 481-500
- **Clinicopathologic and Molecular Characteristics of Merkel Cell Polyomavirus Positive T-cell Lymphoproliferative Disorders**
Bulterys, P., Zhou, C., Gong, S., Gars, E., Zhang, J., Younes, S., Stone, A., Hirt, C., Marks, L., Su, C., Stehr, H., Lawrence, L., Tan, et al
ELSEVIER SCIENCE INC.2026
- **"Leukemic pernio": perniois-like presentations of chronic lymphocytic leukemia.** *Clinical and experimental dermatology*
Gilbert, A., Saleem, A., Kim, Y. H., Khodadoust, M. S., Brown, R. A., Novoa, R. A., Rieger, K. E.
2026
- **Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)**
Miller, R., Wilcox, R., Reneau, J., Yannakou, C., Kim, W., Feldman, T., Kim, Y., Khodadoust, M., Radeski, D., Gasiorowski, R., Yoon, D., Song, Y., Hotson, et al
ELSEVIER.2025: 778-779
- **Cytotoxic lymphoma assessment response (CLyAR): A harmonized, compartment-based consensus response assessment framework for cytotoxic T-cell lymphomas**
Iyer, S., Allen, P., Khodadoust, M., Marchi, E., Gru, A., Thornton, S., Gruenbaum, L., Gutierrez, M., Lohray, R., Kim, W., Nair, R., Torres-Cabala, C., Kim, et al
ELSEVIER.2025: 1871
- **T-cell clones of uncertain significance are prevalent in cutaneous T-cell lymphomas**
Najidh, S., Cleveland, J., Burke, R., Torres, A., Kwang, A., Duran, G., Cooper, Y., Kirsch, I., Zhang, B., Kim, Y., Khodadoust, M.
ELSEVIER.2025: 5431-5432
- **Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas**
Horwitz, S., Zain, J., Querfeld, C., Kim, Y., Khodadoust, M., Andali, T., Kim, W., Poh, C., Yannakou, C., Reneau, J., Brammer, J., Pellegrini, C., Zinzani, et al
ELSEVIER.2025
- **A Phase 2 Study of Low-Dose Total Skin Electron Beam Therapy (LD-TSEBT) Combined with Mogamulizumab (TSE-Moga) in patients with Mycosis Fungoides (MF) and Sezary Syndrome (SS)**
Surjanto, K., Wang, E. B. K., Bandali, T., Ahmed, Z., Sinha, K., Herrera, M., Li, S., Binkley, M. S., Hiniker, S., Khodadoust, M. S., Hoppe, R. T., Kim, Y. H.
ELSEVIER SCI LTD.2025
- **<i>JAK2</i> fusions in mycosis fungoides and Sezary Syndrome and treatment with ruxolitinib**
Torres, A., Bandali, T., Surjanto, K., Kwang, A., Duran, G., Kim, Y. H., Khodadoust, M. S.
ELSEVIER SCI LTD.2025: S54-+
- **Addiction of primary cutaneous $\gamma\delta$ T cell lymphomas to JAK/STAT signaling.** *The Journal of clinical investigation*
Zhang, Y., Yescas, J. A., Tefft, K., Ng, S., Qiu, K., Wang, E. B., Akhtar, S., Walker, A., Welborn, M., Zaiac, M., Guitart, J., Qureshi, A. M., Kim, et al
2025; 135 (8)
- **ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.** *Journal of the American Academy of Dermatology*
Goyal, A., O'Leary, D., Dabaja, B., Weng, W. K., Zain, J., Cutler, C., Guitart, J., Kim, Y. H., Geskin, L. J., Hoppe, R. T., Wilson, L. D., Beaven, A. W., Horwitz, et al
2025
- **Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.** *Nature communications*
Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., Maltos, A. M., Silva, O., Stehr, H., Hovanky, V., Duran, G., Zhang, T., Liedtke, et al
2025; 16 (1): 1824

- **Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma.** *Leukemia & lymphoma*
Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., Kim, Y. H., Wilcox, R. A., Patel, M. R., Coffey, G., Innes, A., Betz, A., Holland, et al
2025: 1-11
- **Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.** *The Lancet. Oncology*
Iyer, S. P., Sica, R. A., Ho, P. J., Prica, A., Zain, J., Foss, F. M., Hu, B., Beitinjaneh, A., Weng, W. K., Kim, Y. H., Khodadoust, M. S., Huen, A. O., Williams, et al
2024
- **Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.** *Nature medicine*
Horwitz, S. M., Nirmal, A. J., Rahman, J., Xu, R., Drill, E., Galasso, N., Ganesan, N., Davey, T., Hancock, H., Perez, L., Maccaro, C., Bahgat, A., Marzouk, et al
2024
- **Long-Term Outcomes with Mogamulizumab Alone or in Combination with Other Therapies for the Treatment of Cutaneous T-Cell Lymphoma**
Bojanini, L., Herrera, M., Li, S., Bandali, T., Xu, N. Y., Ahmed, A. A., Khodadoust, M. S., Kim, Y. H.
ELSEVIER.2024: 1677-1678
- **Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization**
Zain, J., Iyer, S. P., Marchi, E., Gandhi, M., Kim, Y. H., Khodadoust, M. S., Brammer, J. E., Poh, C., Porcu, P., Dilley, K., Will, M., Kantor, A., Leonowens, et al
ELSEVIER.2024: 980-982
- **Integrating Genomic & Transcriptomic Features for Noninvasive Detection, Characterization, and Monitoring of T-Cell Lymphomas**
Sugio, T., Nesselbush, M., Shukla, N., Garofalo, A., Mutter, J. A., Esfahani, M., Alig, S. K., Shi, S., Noordenbos, T., Hamilton, M. P., Rossi, C., Tian, F., Liu, et al
ELSEVIER.2024: 454-455
- **Molecular Residual Disease Detection Via Cancer Personalized Profiling By Deep Sequencing in Patients with PTCL Undergoing Autologous Stem Cell Transplantation**
Sanghera, C., Ford, J., Gunaratne, R., Chopra, K., Rider, A. B., Sohani, A. R., McCabe, S. M., Nemec, R. A., Chen, Y., Mcafee, S., Hochberg, E., Barnes, J. A., Macvicar, et al
ELSEVIER.2024: 6202-6203
- **Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial**
Bagot, M., Kim, Y. H., Ram-Wolff, C., Dalle, S., Mehta-Shah, N., Huen, A., Poligone, B., Zinzani, P., Geskin, L. J., Duval-Modeste, A., Ortiz-Romero, P. L., Sokol, L., Woei-A-Jin, et al
ELSEVIER.2024: 467-468
- **Lacutamab in Patients with Relapsed and/or Refractory Sezary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial**
Battistella, M., Gru, A. A., Moins-Teisserenc, H., Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Sokol, L., Beylot-Barry, et al
ELSEVIER.2024
- **Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival**
Gunaratne, R., Zhou, C., Tai, J. W., Kim, S., Tanaka, K., Rajaram, S., Carleton, M., Yin, R., Alkaitis, M., Schwede, M., Sworder, B. J., Khodadoust, M. S., Majeti, et al
ELSEVIER.2024: 2955-2956
- **Indolent CD8+CAR T-Cell Lymphoma of the Gastrointestinal Tract after Ciltacabtagene Autoleucl Therapy for Relapsed/Refractory Multiple Myeloma**
Hosoya, H., Fernandez-Pol, S., Gubatan, J., Ehlinger, Z., Lohman, C., Torres, A., Najidh, S., Kwang, A., Duran, G., Wright, C., Kennedy, V. E., Bharadwaj, S., Smith, et al
ELSEVIER.2024: 4846-4847

- **ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome.** *Transplantation and cellular therapy*
Goyal, A., O'Leary, D., Dabaja, B., Weng, W. K., Zain, J., Cutler, C., Guitart, J., Kim, Y. H., Geskin, L. J., Hoppe, R. T., Wilson, L. D., Beaven, A. W., Horwitz, et al
2024
- **Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.** *Nature medicine*
Horwitz, S. M., Nirmal, A. J., Rahman, J., Xu, R., Drill, E., Galasso, N., Ganesan, N., Davey, T., Hancock, H., Perez, L., Maccaro, C., Bahgat, A., Marzouk, et al
2024
- **Long-term remission with allogeneic transplant in patients with refractory/relapsed cutaneous cytotoxic T-cell lymphoma.** *Blood neoplasia*
Weng, W. K., Iragavarapu, C., Weng, G. M., Hoppe, R. T., Hiniker, S., Khodadoust, M. S., Kim, Y. H.
2024; 1 (2): 100007
- **Multi-omic profiling reveals the endogenous and neoplastic responses to immunotherapies in cutaneous T cell lymphoma.** *Cell reports. Medicine*
Glass, D. R., Mayer-Blackwell, K., Ramchurren, N., Parks, K. R., Duran, G. E., Wright, A. K., Bastidas Torres, A. N., Islas, L., Kim, Y. H., Fling, S. P., Khodadoust, M. S., Newell, E. W.
2024: 101527
- **A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.** *Cell stem cell*
Kastenschmidt, J. M., Schroers-Martin, J. G., Sworder, B. J., Sureshchandra, S., Khodadoust, M. S., Liu, C. L., Olsen, M., Kurtz, D. M., Diehn, M., Wagar, L. E., Alizadeh, A. A.
2024
- **Specificity of Immunoglobulin High-Throughput Sequencing Minimal Residual Disease Monitoring in Non-Hodgkin Lymphomas.** *Blood advances*
Shukla, N., Schroers-Martin, J., Sworder, B., Kathuria, K. R., Alig, S., Frank, M. J., Miklos, D. B., Coutre, S. E., Diehn, M., Khodadoust, M. S., Roschewski, M. J., Kurtz, D. M., Alizadeh, et al
2023
- **Two cases of mycosis fungoides with large cell transformation with KMT2A rearrangements.** *Journal of hematopathology*
Wadsworth, P. A., Lawrence, L., Suarez, C. J., Saleem, A., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., Fernandez-Pol, S.
2023; 16 (4): 227-234
- **A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single cell analysis.** *Blood advances*
Shree, T., Haebe, S. E., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L., Alizadeh, A. A., Advani, R. H., Hoppe, R. T., Long, et al
2023
- **Lacutamab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial**
Bagot, M., Kim, Y. H., Geskin, L. J., Ortiz-Romero, P. L., Kim, E., Mehta-Shah, N., Dereure, O., Oro, S., Beylot-Barry, M., Dalle, S., Jacobsen, E., Lansigan, F., Ram-Wolff, et al
AMER SOC HEMATOLOGY.2023
- **Development of Circulating Tumor DNA (ctDNA) for Molecular Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)**
Gunaratne, R., Zhou, C., Tai, J. W., Schwede, M., Tanaka, K., Alkaitis, M., Yin, R., Sworder, B. J., Mannis, G., Majeti, R., Khodadoust, M. S., Kurtz, D. M., Zhang, et al
AMER SOC HEMATOLOGY.2023
- **An Integrated Multimodal Framework for Noninvasive TCL Disease Detection and Monitoring**
Sugio, T., Shukla, N., Khodadoust, M. S., Nesselbush, M., Kato, K., Alig, S. K., Boegeholz, J., Schroers-Martin, J., Esfahani, M., Mutter, J. A., Garofalo, A., Jun, S., Hamilton, et al
AMER SOC HEMATOLOGY.2023
- **Machine Learning-Based Survival Analysis Reveals Prognostic Clinical and Genetic Insights for Patients with Cutaneous T-Cell Lymphoma**
Schreidah, C. M., DeStephano, D. M., Pan, S. S., Wang, S., Shen, H., Ta, C. N., Reynolds, G., Fahmy, L. M., Gordon, E. R., Adeuyan, O., Kwinta, B. D., Stonesifer, C. J., Chan, et al
AMER SOC HEMATOLOGY.2023

- **Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration By Balancing Efficacy and Tolerability**
Munayirji, B., Khan, N., Myskowski, P., Geller, S., Noor, S., Kheterpal, M., Davey, T., Hancock, H., Perez, L., Miller, T., Brutus, J., Ganesan, N., Chang, et al
AMER SOC HEMATOLOGY.2023
- **Elucidating genetic factors of cutaneous T-cell lymphoma staging and disease severity through machine learning**
Schreidah, C. M., Reynolds, G., Shen, H., Fahmy, L. M., Choi, J., Duvic, M., Gallardo, F., Girardi, M., Guitart, J., Kim, Y. H., Khodadoust, M., Najidh, S., Ni, et al
ELSEVIER SCI LTD.2023: S15
- **Genomic abnormalities involving class I HLA are common in advanced cutaneous T-cell lymphoma**
Kwang, A., Duran, G., Fernandez-Pol, S., Li, S., Najidh, S., Torres, A., Herrera, M., Wang, E., Kurtz, D., Kim, Y. H., Khodadoust, M.
ELSEVIER SCI LTD.2023: S14
- **Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study**
Bagot, M., Kim, Y. H., Ortiz-Romero, P. L., Zinzani, P., Beylot-Barry, M., Dalle, S., Jacobsen, E., Combalia, A., Huen, A., Mehta-Shah, N., Khodadoust, M., Mehta, A., Dereure, et al
ELSEVIER SCI LTD.2023: S19-S20
- **Identification and confirmation via in situ hybridization of Merkel cell polyomavirus in rare cases of posttransplant cutaneous T-cell lymphoma.** *Journal of cutaneous pathology*
Lawrence, L., Wang, A., Charville, G., Liu, C. L., Garofalo, A., Alizadeh, A., Jangam, D., Pinsky, B. A., Sahoo, M., Gratzinger, D., Khodadoust, M., Kim, Y., Novoa, et al
2023
- **Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors.** *Cancer discovery*
Schroers-Martin, J. G., Soo, J., Brisou, G., Scherer, F., Kurtz, D. M., Sworder, B. J., Khodadoust, M. S., Jin, M. C., Bru, A., Liu, C. L., Stehr, H., Vineis, P., Natkunam, et al
2023
- **Minimal/measurable residual disease (MRD) monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor.** *The Journal of molecular diagnostics : JMD*
Tung, J. K., Jangam, D., Ho, C. C., Fung, E., Khodadoust, M. S., Kim, Y. H., Zehnder, J. L., Stehr, H., Zhang, B. M.
2023
- **Hepatosplenic T-cell lymphoma with STAT5B and SETD2 mutations recurring as cells with NK-cell immunophenotype.** *Blood*
Khodadoust, M., Silva, O.
2023; 141 (5): 555
- **Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.** *Cancer cell*
Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Shahrokh Esfahani, M., Olsen, M. N., Hamilton, J., Hosoya, H., Hamilton, M., Spiegel, et al
2022
- **Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma**
Shree, T., Haebe, S., Czerwinski, D. K., Eckhert, E., Day, G., Sathe, A., Grimes, S. M., Frank, M. J., Maeda, L. S., Alizadeh, A. A., Advani, R. H., Hoppe, R., Long, et al
AMER SOC HEMATOLOGY.2022: 6450-6451
- **ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas**
Song, Y., Ding, N., Yoon, D., Reneau, J. C., Wilcox, R. A., Kim, W., Kim, Y. H., Khodadoust, M. S., Feldman, T. A., Yannakou, C. K., Giri, P., Brammer, J. E., Hsu, et al
AMER SOC HEMATOLOGY.2022: 8857-8859
- **Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-Cell Lymphomas**
Mou, E., Fernandez-Pol, S., Li, S., Kim, Y. H., Khodadoust, M. S.
AMER SOC HEMATOLOGY.2022: 6552-6553
- **Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial**

- Bagot, M., Kim, Y. H., Ortiz-Romero, P. L., Zinzani, P., Mehta-Shah, N., Dereure, O., Beylot-Barry, M., Dalle, S., Jacobsen, E. D., Huen, A., Combalia, A., Battistella, M., Gru, et al
AMER SOC HEMATOLOGY.2022: 3760-3761
- **Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA**
Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., Zhang, T. Y., Khodadoust, M. S., Miklos, D. B., Arai, S., Iberri, D., Liedtke, M., Sidana, et al
AMER SOC HEMATOLOGY.2022: 1546-1548
 - **Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas**
Sworder, B., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N. D., Garofalo, A., Macaulay, C., Esfahani, M., Olsen, M., Hamilton, J., Hosoya, H., Hamilton, M. P., Spiegel, et al
AMER SOC HEMATOLOGY.2022: 1301-1303
 - **Specificity & Precision of Minimal Residual Disease Monitoring in DLBCL Using Ig-HTS**
Shukla, N. D., Schroers-Martin, J., Kathuria, K. R., Sworder, B., Alig, S. K., Frank, M. J., Miklos, D. B., Coutre, S., Diehn, M., Khodadoust, M. S., Roschewski, M., Kurtz, D. M., Alizadeh, et al
AMER SOC HEMATOLOGY.2022: 6403-6404
 - **CYTOF AND SERUM PROTEOMICS SHOW DISTINCT DIFFERENCES IN IMMUNE RESPONSES BETWEEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME TO MONO- AND COMBINATION ANTI-PD-1 IMMUNOTHERAPY**
Ramchurren, N., Parks, R., Islas, L., Fling, S., Khodadoust, M., Newell, E., Glass, D.
BMJ PUBLISHING GROUP.2022: A103
 - **Correlation of sTNFR2 elevation and disease progression in cutaneous T cell lymphomas**
Lee, A., Kim, Y., Khodadoust, M., Faustman, D. L.
AMER ASSOC CANCER RESEARCH.2022
 - **CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.** *Blood cancer discovery*
Shree, T., Shankar, V., Lohmeyer, J. J., Czerwinski, D. K., Schroers-Martin, J. G., Rodriguez, G. M., Beygi, S., Kanegai, A. M., Corbelli, K. S., Gabriel, E., Kurtz, D. M., Khodadoust, M. S., Gupta, et al
2022
 - **Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma**
Shree, T., Shankar, V., Czerwinski, D. K., Rodriguez, G., Beygi, S., Schroers-Martin, J. G., Advani, R., Maeda, L. S., Gupta, N. K., Khodadoust, M. S., Kurtz, D. M., Corbelli, K. S., Gabriel, et al
AMER SOC HEMATOLOGY.2021
 - **Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral TCell Lymphoma**
Horwitz, S. M., Feldman, T. A., Ye, J. C., Khodadoust, M. S., Munoz, J., Hamlin, P. A., Kim, Y. H., Wilcox, R. A., Patel, M. R., Coffey, G. P., Osman, M., Holland, J. S., Guzman, et al
AMER SOC HEMATOLOGY.2021
 - **Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation**
Shree, T., Haebe, S., Czerwinski, D. K., Day, G., Sathe, A., Khodadoust, M. S., Frank, M. J., Beygi, S., Hoppe, R., Long, S. R., Martin, B., Ji, H. P., Levy, et al
AMER SOC HEMATOLOGY.2021
 - **Two Cases of Mycosis Fungoides With PCM1-JAK2 Fusion.** *JCO precision oncology*
Fernandez-Pol, S., Neishaboori, N., Chapman, C. M., Khodadoust, M. S., Kim, Y. H., Rieger, K. E., Suarez, C. J.
2021; 5: 646-652
 - **Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.** *European journal of cancer (Oxford, England : 1990)*
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., Herr, F., Bagot, M.
2021; 156 Suppl 1: S48-S49
 - **Primary cytotoxic T cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway**

- Lee, K., Evans, M. G., Yang, L., Ng, S., Snowden, C., Khodadoust, M., Brown, R. A., Trum, N., Querfeld, C., Doan, L. T., Song, J., Zhang, H., Wood, et al
ELSEVIER SCI LTD.2021: S8-S9
- **Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study**
Kim, Y. H., Khodadoust, M., de Masson, A., Moins-Teisserenc, H., Ito, T., Dwyer, K., Herr, F., Bagot, M.
ELSEVIER SCI LTD.2021: S48-S49
 - **Mechanisms of resistance to anti-CCR4 antibody, mogamulizumab, in cutaneous T cell lymphoma**
Beygi, S., Fernandez-Pol, S., Duran, G., Wang, E. B., Kim, Y., Khodadoust, M.
ELSEVIER SCI LTD.2021: S8
 - **Primary Cytotoxic T Cell Lymphomas Harbor Recurrent Targetable Alterations in the JAK-STAT Pathway. *Blood***
Lee, K., Evans, M. G., Yang, L., Ng, S., Snowden, C., Khodadoust, M. S., Brown, R. A., Trum, N. A., Querfeld, C., Doan, L. T., Song, J., Zhang, H., Gru, et al
2021
 - **Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the Tumor Microenvironment by CODEX Tissue Imaging *FRONTIERS IN IMMUNOLOGY***
Phillips, D., Schuerch, C. M., Khodadoust, M. S., Kim, Y. H., Nolan, G. P., Jiang, S.
2021; 12: 687673
 - **Low-Dose Total Skin Electron Beam Therapy Combined With Mogamulizumab for Refractory Mycosis Fungoides and Sezary Syndrome. *Advances in radiation oncology***
Fong, S., Hong, E. K., Khodadoust, M. S., Li, S., Hoppe, R. T., Kim, Y. H., Hiniker, S. M.
2021; 6 (3): 100629
 - **Radiation Therapy for Primary Cutaneous Gamma Delta Lymphoma Prior to Stem Cell Transplantation. *Cancer investigation***
Wu, Y. F., Skinner, L., Lewis, J., Khodadoust, M. S., Kim, Y. H., Kwong, B. Y., Weng, W., Hoppe, R. T., Sodji, Q., Hui, C., Kastelowitz, N., Fernandez-Pol, S., Hiniker, et al
2021: 1–11
 - **Clinical Characterization of Mogamulizumab-Associated Rash During Treatment of Mycosis Fungoides or Sezary Syndrome. *JAMA dermatology***
Hirotsu, K. E., Neal, T. M., Khodadoust, M. S., Wang, J. Y., Rieger, K. E., Strelow, J., Hong, E., Kim, Y. H., Kwong, B. Y.
2021
 - **Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma. *Nature communications***
Phillips, D., Matusiak, M., Gutierrez, B. R., Bhate, S. S., Barlow, G. L., Jiang, S., Demeter, J., Smythe, K. S., Pierce, R. H., Fling, S. P., Ramchurren, N., Cheever, M. A., Goltsev, et al
2021; 12 (1): 6726
 - **Two Cases With Features of Lymphocyte Variant Hypereosinophilic Syndrome With STAT3 SH2 Domain Mutations. *The American journal of surgical pathology***
Fernandez-Pol, S., Petersen, B., Murphy, J., Oak, J. S., Wang, E. B., Rieger, K. E., Kim, Y. H., Khodadoust, M. S., Suarez, C. J.
2020
 - **Cutaneous T-cell lymphomas with pathogenic somatic mutations and absence of detectable clonal T-cell receptor gene rearrangement: two case reports. *Diagnostic pathology***
Rojansky, R., Fernandez-Pol, S., Wang, E., Rieger, K. E., Novoa, R. A., Zehnder, J. L., Kunder, C. A., Kim, Y. H., Khodadoust, M. S., Brown, R. A.
2020; 15 (1): 122
 - **Cellular neighborhoods predict pembrolizumab response in cutaneous T cell lymphoma**
Schurch, C. M., Phillips, D. J., Gutierrez, B., Matusiak, M., Bhate, S. S., Barlow, G. L., Fling, S. P., Ramchurren, N., Pierce, R. H., Cheever, M. A., Khodadoust, M. S., West, R., Kim, et al
AMER ASSOC CANCER RESEARCH.2020
 - **A Long-Term Study of Persistent Sézary Syndrome: Evidence for Antigen Shift by Multiparameter Flow Cytometry and Its Significance in Overall Survival. *The American Journal of dermatopathology***
Hoffmann, J. C., Atwater, S. K., Hong, E. n., Kumar, J. n., Khodadoust, M. n., Kim, Y. n., Ohgami, R. S.
2020; 42 (6): 389–96

- **Histopathologic Characterization of Mogamulizumab-associated Rash.** *The American journal of surgical pathology*
Wang, J. Y., Hirotsu, K. E., Neal, T. M., Raghavan, S. S., Kwong, B. Y., Khodadoust, M. S., Brown, R. A., Novoa, R. A., Kim, Y. H., Rieger, K. E.
2020
- **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*
Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al
2020; 4 (18): 4474–82
- **Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.** *The Journal of experimental medicine*
Frank, M. J., Khodadoust, M. S., Czerwinski, D. K., Haabeth, O. A., Chu, M. P., Miklos, D. B., Advani, R. H., Alizadeh, A. A., Gupta, N. K., Maeda, L. S., Reddy, S. A., Laport, G. G., Meyer, et al
2020; 217 (9)
- **Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation**
Kathuria, K. R., Chen, B., Khodadoust, M. S., Olsson, N., Davis, M. M., Elias, J. E., Levy, R., Altman, R. B., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2019
- **A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma**
Shree, T., Khodadoust, M. S., Czerwinski, D. K., Frank, M. J., Hong, W. X., Greenstein, R., Long, S. R., Martin, B., Levy, R.
AMER SOC HEMATOLOGY.2019
- **Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment**
Wagar, L. E., Sworder, B., Khodadoust, M. S., Davis, M. M., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2019
- **A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma**
Mobasher, M., Miller, R. A., Janc, J. W., Kwei, L., Buggy, J. J., Luciano, G., Mohammady, A., Kim, W., Kim, Y. H., Khodadoust, M. S., Horwitz, S. M., Radeski, D.
AMER SOC HEMATOLOGY.2019
- **Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells**
Ng, P. P., Mobasher, M., Yeung, K. S., Hotson, A. N., Hill, C. M., Madriaga, A., Dao-Pick, T. P., Verner, E., Radeski, D., Khodadoust, M. S., Kim, Y. H., Miller, R. A., Buggy, et al
AMER SOC HEMATOLOGY.2019
- **Dynamics of the Cutaneous T Cell Lymphoma Microenvironment in Patients Treated with Pembrolizumab Revealed By Highly Multiplexed Tissue Imaging**
Schuerch, C. M., Phillips, D. J., Bhate, S. S., Barlow, G. L., Fling, S. P., Ramchurren, N., Pierce, R., Cheever, M. A., Khodadoust, M. S., Kim, Y. H., Nolan, G. P.
AMER SOC HEMATOLOGY.2019
- **A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma**
Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., Patel, M. R., Phillips, T. J., Smith, S. D., Smith, S. M., Wilcox, R. A., Birrell, M. R., Leeds, et al
AMER SOC HEMATOLOGY.2019
- **Antagonism of TNFR2: Focus on novel antibodies with preference for tumor microenvironment Tregs and oncogenes expressed on the tumor**
Khodadoust, M., Kim, Y., Yang, M., Torrey, H., Tran, L., Faustman, D.
BMC.2019
- **Interim results of a Phase I/II trial of intratumoral CpG, local low-dose radiation, and oral ibrutinib in patients with low-grade B-cell lymphoma**
Shree, T., Khodadoust, M. S., Czerwinski, D., Frank, M. J., Hong, W. X., Greenstein, R., Guo, S., Long, S., Martin, B. A., Levy, R.
AMER ASSOC CANCER RESEARCH.2019

- **IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.** *The Lancet. Oncology*
Bagot, M., Porcu, P., Marie-Cardine, A., Battistella, M., William, B. M., Vermeer, M., Whittaker, S., Rotolo, F., Ram-Wolff, C., Khodadoust, M. S., Bensussan, A., Paturel, C., Bonnafous, et al
2019
- **Low-dose Total Skin Electron Beam Therapy for Refractory Cutaneous CD30 Positive Lymphoproliferative Disorders.** *The Journal of dermatological treatment*
Panjwani, N., Yoo, C. H., Wang, E., Khodadoust, M. S., Kim, Y. H., Hoppe, R. T., Hiniker, S. M.
2019: 1–5
- **Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019; 37 (9): 755-+
- **Volumetric modulated arc therapy and 3-dimensional printed bolus in the treatment of refractory primary cutaneous gamma delta lymphoma of the bilateral legs.** *Practical radiation oncology*
Obeid, J., Gutkin, P. M., Lewis, J., Skinner, L., Wang, E. B., Khodadoust, M. S., Kim, Y. H., Weng, W., Hoppe, R. T., Hiniker, S. M.
2019
- **B-cell lymphomas present immunoglobulin neoantigens** *BLOOD*
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B., Shree, T., Liu, C., Zhang, L., Czerwinski, D. K., Davis, M. M., Levy, R., Elias, J. E., Alizadeh, A. A.
2019; 133 (8): 878–81
- **Reply to J. Wang et al.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2019: JCO1801907
- **Determining cell type abundance and expression from bulk tissues with digital cytometry.** *Nature biotechnology*
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F. n., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D. n., Diehn, M. n., Alizadeh, A. A.
2019
- **Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucef Therapy** *American Society of Hematology*
Sworder, B., Kurtz, D. M., Macaulay, C., Frank, M. J., Alig, S., Garofalo, A., Sahaf, B., Esfahani, M. S., Spiegel, J. Y., Oak, J., Beygi, S., Jin, M. C., Chabon, et al
2019
- **Predicting HLA class II antigen presentation through integrated deep learning.** *Nature biotechnology*
Chen, B. n., Khodadoust, M. S., Olsson, N. n., Wagar, L. E., Fast, E. n., Liu, C. L., Muftuoglu, Y. n., Sworder, B. J., Diehn, M. n., Levy, R. n., Davis, M. M., Elias, J. E., Altman, et al
2019
- **Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin.** *PLoS one*
Narayan, R. n., Olsson, N. n., Wagar, L. E., Medeiros, B. C., Meyer, E. n., Czerwinski, D. n., Khodadoust, M. S., Zhang, L. n., Schultz, L. n., Davis, M. M., Elias, J. E., Levy, R. n.
2019; 14 (7): e0219547
- **Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Final Results from a Phase 2 Multicenter Study**
Khodadoust, M. S., Rook, A., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., Shanbhag, S., Sokol, L., Fling, S. P., Li, S., Davis, A., Fong, S., Kim, et al
AMER SOC HEMATOLOGY.2018
- **The Combination of Duvelisib, a PI3K-delta,gamma Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts**
Horwitz, S. M., Moskowitz, A. J., Jacobsen, E. D., Mehta-Shah, N., Khodadoust, M. S., Fisher, D. C., Myskowski, P., Wang, E. B. K., Tawa, M., Davey, T., Blouin, W., Hancock, H., Ganesan, et al

AMER SOC HEMATOLOGY.2018

- **IPH4102; An Anti-KIR3DL2 Monoclonal Antibody in Refractory Sezary Syndrome: Results from a Multicenter Phase 1 Trial**
Bagot, M., Porcu, P., William, B. M., Battistella, M., Vermeer, M., Whittaker, S., Ram-Wolff, C., Khodadoust, M. S., Sicard, H., Azim, H. A., Kim, Y. H.
AMER SOC HEMATOLOGY.2018
- **The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/ Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma**
Horwitz, S. M., Feldman, T. A., Hess, B. T., Khodadoust, M. S., Kim, Y. H., Munoz, J., Patel, M. R., Phillips, T. J., Smith, S. D., Smith, S. M., Wilcox, R. A., Steele, A., Pandey, et al
AMER SOC HEMATOLOGY.2018
- **Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome.** *Leukemia*
Torrey, H., Khodadoust, M., Tran, L., Baum, D., Defusco, A., Kim, Y. H., Faustman, D. L.
2018
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma** *JOURNAL OF CLINICAL ONCOLOGY*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018; 36 (28): 2845-+
- **Pembrolizumab in mycosis fungoides and Sezary syndrome: Updated results of the CITN multicenter Phase 2 study**
Khodadoust, M. S., Rook, A. H., Porcu, P., Foss, F., Moskowitz, A., Shustov, A. R., Shanbhag, S., Sokol, L., Fling, S. P., Li, S., Fong, S., Kim, J., Yang, et al
ELSEVIER SCI LTD.2018: S37
- **Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies**
Torrey, H., Defusco, A., Baum, D., Rhabar, Z., Khodadoust, M., Kim, Y. H., Faustman, D. L.
AMER ASSOC CANCER RESEARCH.2018
- **IPH4102 in relapsed/refractory cutaneous T cell lymphoma (CTCL): Results of the first-in-human multicenter phase 1 study**
Bagot, M., Porcu, P., William, B., Vermeer, M., Whittaker, S., Wolff, C., Khodadoust, M., Battistella, M., Paiva, C., Sicard, H., Azim, H., Kim, Y.
ELSEVIER SCI LTD.2018: S29
- **Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
2018: JCO2018785246
- **Surgical and molecular characterization of primary and metastatic disease in a neuroendocrine tumor arising in a tailgut cyst.** *Cold Spring Harbor molecular case studies*
Erdrich, J., Schaberg, K., Khodadoust, M. S., Zhou, L., Shelton, A. A., Visser, B. C., Ford, J. M., Alizadeh, A. A., Quake, S. R., Kunz, P. L., Beausang, J. F.
2018
- **TNFR2-targeted elimination of Tregs and tumor-residing T cells in advanced cutaneous T cell lymphoma**
Faustman, D. L., Torrey, H., Khodadoust, M., Defusco, A., Baum, D., Rahbar, Z., Kim, Y. H.
AMER ASSOC CANCER RESEARCH.2018
- **Profiling Tumor Infiltrating Immune Cells with CIBERSORT.** *Methods in molecular biology (Clifton, N.J.)*
Chen, B. n., Khodadoust, M. S., Liu, C. L., Newman, A. M., Alizadeh, A. A.
2018; 1711: 243-59
- **Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.** *JAMA dermatology*
Dai, J. n., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S. n., Weng, W. K., Kim, Y. H.
2018
- **Transcript-indexed ATAC-seq for precision immune profiling.** *Nature medicine*

- Satpathy, A. T., Saligrama, N. n., Buenrostro, J. D., Wei, Y. n., Wu, B. n., Rubin, A. J., Granja, J. M., Lareau, C. A., Li, R. n., Qi, Y. n., Parker, K. R., Mumbach, M. R., Serratelli, et al
2018
- **T-cell immunopeptidomes reveal cell subtype surface markers derived from intracellular proteins.** *Proteomics*
Olsson, N. n., Schultz, L. M., Zhang, L. n., Khodadoust, M. S., Narayan, R. n., Czerwinski, D. K., Levy, R. n., Elias, J. E.
2018
 - **Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma**
Kurtz, D. M., Scherer, F., Jin, M., Soo, J., Craig, A., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, et al
AMER SOC HEMATOLOGY.2017
 - **In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K-delta,gamma Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma**
Moskowitz, A. J., Koch, R., Mehta-Shah, N., Myskowski, P., Kheterpal, M., Dogan, A., Davey, T., Galasso, N., Evan, M., Shah, M., Ganesan, N., Lubin, L., Kim, et al
AMER SOC HEMATOLOGY.2017
 - **Maria: Accurate Prediction of MHC-II Peptide Presentation with Deep-Learning and Lymphoma Patient MHC-II Ligandome**
Chen, B., Khodadoust, M., Olsson, N., Fast, E., Wagar, L. E., Liu, C., Davis, M., Levy, R., Elias, J. E., Altman, R. B., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2017
 - **Novel treatment of cutaneous T cell lymphoma: Targeting TNFR2, an oncogene and marker of potent Tregs, with anti-TNFR2 antibodies**
Torrey, H., Defusco, A., Baum, D., Rahbar, Z., Khodadoust, M., Kim, Y. H., Faustman, D.
BMC.2017
 - **On the hunt for cancer neoantigens: is mass spectrometry the solution?**
Elias, J., Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Green, M. R., Davis, M. M., Levy, R., Alizadeh, A. A.
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC.2017: S65
 - **Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.**
Jin, M. C., Kurtz, D., Esfahani, M., Scherer, F., Craig, A. F. M., Soo, J., Khodadoust, M., Saganty, R., Chabon, J. J., Schroers-Martin, J., Stehr, H., Advani, R. H., Rossi, et al
AMER SOC CLINICAL ONCOLOGY.2017
 - **Antigen presentation profiling reveals T-cell recognition of lymphoma immunoglobulin neoantigens**
Olsson, N., Khodadoust, M., Wagar, L., Swaminathan, K., Haabeth, O., Chen, B., Rawson, K., Liu, C., Steiner, D., Lund, P. J., Rao, S., Zhang, L., Marceau, et al
AMER ASSOC IMMUNOLOGISTS.2017
 - **Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.** *Cancer discovery*
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H. n., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L. n., Scherer, F. n., Kurtz, D. M., Say, et al
2017
 - **Antigen Presentation Profiling Reveals T-Cell Recognition of Lymphoma Immunoglobulin Neoantigens**
Khodadoust, M., Olsson, N., Wagar, L., Chen, B., Rawson, K., Liu, C., Steiner, D., Rao, S., Zhang, L., Stehr, H., Newman, A. M., Czerwinski, D. K., Carlton, et al
AMER SOC HEMATOLOGY.2016
 - **Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cytometry in Previously Untreated Patients**
Czerwinski, D. K., Long, S. R., Khodadoust, M., Frank, M. J., Kardosh, A., Okada, A., Robinson, S., Levy, R.
AMER SOC HEMATOLOGY.2016
 - **SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial**
Levy, R., Reagan, P. M., Friedberg, J. W., Bartlett, N. L., Gordon, L. I., Leung, A., Peterkin, J., Xing, B., Coffman, R., Janssen, R., Candia, A., Khodadoust, M., Frank, et al
AMER SOC HEMATOLOGY.2016

- **Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study**
Khodadoust, M., Rook, A. H., Porcu, P., Foss, F. M., Moskowitz, A. J., Shustov, A. R., Shanbhag, S., Sokol, L., Shine, R., Fling, S. P., Li, S., Rabhar, Z., Kim, et al
AMER SOC HEMATOLOGY.2016
- **First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results**
Bagot, M., Porcu, P., Ram-Wolff, C., Khodadoust, M., Battistella, M., Marie-Cardine, A., Mathieu, S., Vermeer, M. H., Whittaker, S., Duvic, M., Bensussan, A., Paturel, C., Bonnafous, et al
AMER SOC HEMATOLOGY.2016
- **A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT)**
Kim, Y. H., Hoppe, R. T., Rook, A. H., Maity, A., Geskin, L. J., Horowitz, D. P., Finnegan, G., Khodadoust, M., Weng, W., Lares, A., Hong, E., Buchanan, M., Ma, et al
AMER SOC HEMATOLOGY.2016
- **SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial**
Levy, R., Bartlett, N., Friedberg, J., Reagan, P., Gordon, L., Bergman, C., Coffman, R., Janssen, R., Candia, A., Khodadoust, M., Frank, M., Long, S., Czerwinski, et al
AMER ASSOC CANCER RESEARCH.2016
- **Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.**
Kurtz, D., Scherer, F., Newman, A. M., Craig, A. F. M., Khodadoust, M., Lovejoy, A. F., Klass, D. M., Chabon, J. J., Glover, C., Zhou, L., Liu, C., Gupta, N. K., Maeda, et al
AMER SOC CLINICAL ONCOLOGY.2016
- **Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. *Leukemia***
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., Bangs, C. D., Cherry, A. M., Arai, S., Arber, D. A., Zehnder, J. L., Gotlib, J.
2016; 30 (4): 947-950
- **Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis**
Chu, M. P., Brody, J., Kohrt, H. E., Frank, M. J., Khodadoust, M., Reddy, S., Advani, R. H., Gupta, N. K., Laport, G., Maeda, L. S., Meyer, E., Miklos, D. B., Negrin, et al
AMER SOC HEMATOLOGY.2015
- **T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC**
Schultz, L. M., Olsson, N., Khodadoust, M., Narayan, R., Sagiv-Barfi, I., Elias, J., Levy, R.
AMER SOC HEMATOLOGY.2015
- **Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN**
Czerwinski, D. K., Long, S. R., Khodadoust, M., Frank, M. J., Chu, M. P., Okada, A., McDonald, K. A., Kohrt, H. E., Bartlett, N. L., Reagan, P. M., Friedberg, J. W., Gordon, L. I., Coffman, et al
AMER SOC HEMATOLOGY.2015
- **Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipilimumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.**
Khodadoust, M., Chu, M., Czerwinski, D., McDonald, K., Long, S., Kohrt, H., Hoppe, R. T., Advani, R. H., Lowsky, R., Levy, R.
AMER SOC CLINICAL ONCOLOGY.2015
- **Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.**
Kurtz, D., Scherer, F., Green, M., Khodadoust, M., Klass, D. M., Zhou, L., Krishnan, R., Glover, C., Liu, C., Kong, K. A., Faham, M., Levy, R., Diehn, et al
AMER SOC CLINICAL ONCOLOGY.2015
- **Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era. *International journal of radiation oncology, biology, physics***

- Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Xu, G., Quon, A., Advani, R. H., Hoppe, R. T.
2015; 92 (1): 99-106
- **Prognostic Factors, Treatment, and Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab (R) Era**
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., Hoppe, R. T.
ELSEVIER SCIENCE INC.2014: S677–S678
 - **Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era.**
Hiniker, S. M., Pollom, E. L., Khodadoust, M. S., Kozak, M. M., Advani, R. H., Hoppe, R. T.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Tumor antigen discovery through translation of the cancer genome.** *Immunologic research*
Khodadoust, M. S., Alizadeh, A. A.
2014; 58 (2-3): 292-299
 - **DEK expression in melanocytic lesions** *HUMAN PATHOLOGY*
Kappes, F., Khodadoust, M. S., Yu, L., Kim, D. S., Fullen, D. R., Markovitz, D. M., Ma, L.
2011; 42 (7): 932-938
 - **The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity** *GENES & DEVELOPMENT*
Kappes, F., Waldmann, T., Mathew, V., Yu, J., Zhang, L., Khodadoust, M. S., Chinnaiyan, A. M., Luger, K., Erhardt, S., Schneider, R., Markovitz, D. M.
2011; 25 (7): 673-678
 - **Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene** *CANCER RESEARCH*
Khodadoust, M. S., Verhaegen, M., Kappes, F., Riveiro-Falkenbach, E., Cigudosa, J. C., Kim, D. S., Chinnaiyan, A. M., Markovitz, D. M., Soengas, M. S.
2009; 69 (16): 6405-6413
 - **DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress** *MOLECULAR AND CELLULAR BIOLOGY*
Kappes, F., Fahrner, J., Khodadoust, M. S., Tabbert, A., Strasser, C., Mor-Vaknin, N., Moreno-Villanueva, M., Buerkle, A., Markovitz, D. M., Ferrando-May, E.
2008; 28 (10): 3245-3257
 - **The DEK nuclear autoantigen is a secreted chemotactic factor** *MOLECULAR AND CELLULAR BIOLOGY*
Mor-Vaknin, N., Punturieri, A., Sitwala, K., Faulkner, N., Legendre, M., Khodadoust, M. S., Kappes, F., Ruth, J. H., Koch, A., Glass, D., Petruzzelli, L., Adams, B. S., Markovitz, et al
2006; 26 (24): 9484-9496
 - **The DEK nuclear protein autoantigen is secreted chemotactic factor**
Mor-Vaknin, N., Punturieri, A., Sitwala, K., Faulkner, N., Legendre, M., Khodadoust, M. S., Burrell, B. E., Ruth, J. H., Koch, A., Glass, D., Petruzzelli, L., Adams, B., Markovitz, et al
AMER ASSOC IMMUNOLOGISTS.2006: S132
 - **p300/CBP-associated factor drives DEK into interchromatin granule clusters** *JOURNAL OF BIOLOGICAL CHEMISTRY*
Cleary, J., Sitwala, K. V., Khodadoust, M. S., Kwok, R. P., Mor-Vaknin, N., Cebrat, M., Cole, P. A., Markovitz, D. M.
2005; 280 (36): 31760-31767
 - **The nuclear protein DEK, a putative autoantigen in JRA, is secreted by activated human macrophages and exhibits chemokine activity.**
Mor-Vaknin, N., Punturieri, A., Sitwala, K., Faulkner, N., Legendre, M., Cleary, J., Khodadoust, M. S., Burrell, B., Ruth, J. H., Koch, A. E., Glass, D. N., Petruzzelli, L., Adams, et al
WILEY-BLACKWELL.2005: S442
 - **Induction of apoptosis in lymphoid cell lines and primary CLL by HA14-1, a cell permeable organic small molecule that binds to the BH1 to BH3 surface pocket of Bcl-2 protein.**
Hu, G. Y., Khodadoust, M., Konopleva, M., Huang, Z. W., Andreeff, M.
AMER SOC HEMATOLOGY.2001: 840A
 - **Bcl-2 antisense oligodeoxynucleotide (Genasense) enhances gemtuzumab ozogamicin (Mylotarg)-induced cytotoxicity in acute myeloid leukemia.**
Khodadoust, M., Konopleva, M., Leysath, C., Frankel, Giles, F. J., Andreeff, M.

AMER SOC HEMATOLOGY.2001: 102A

- **Induction of apoptosis in primary human leukemia cells by HA14-1, a cell-permeable organic compound identified by protein structure-based computer screening that binds the BH1 to BH3 surface pocket of Bcl-2.**

Andreeff, M., Konopleva, M., Leysath, C., Khodadoust, M., Huang, Z.

AMER ASSOC CANCER RESEARCH.2001: 3722S